The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute myocardial infarction (AMI) and unstable angina, an aging global population ...

The acute coronary syndrome market is experiencing significant growth, driven by the increasing prevalence of both acute ...

Analyst Evan Seigerman of BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report), retaining the price target of $362.00.Stay ...

Today, Benzinga's options scanner spotted 11 options trades for Amgen. This isn't normal. The overall sentiment of these ...

For patients with severe elevations in low-density lipoprotein (LDL) cholesterol (≥190 mg/dL) and a combination of clinical ...

These drugs reduce the cholesterol your body makes and help clear out LDL in your blood vessels where they can leave ...

周二，加拿大皇家银行资本市场 (RBC Capital Markets)调整了安进 (Amgen) (NASDAQ:AMGN)的股价目标，将其从此前的$330下调至$324，同时维持对该股的优于大盘评级。这一调整是基于RBC Capital对公司增长前景的分析，这一前景得到了其成熟产品线、近期收购以及新兴治疗管线的支持。

A high dividend and inclusion in the Dow Jones Average 30 may create the impression of a foolproof investment, but those are ...

We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

The general mood among these heavyweight investors is divided, with 50% leaning bullish and 42% bearish. Among these notable ...

Another trend gaining traction is new biosimilars product offerings. In August 2022, Dr. Reddy’s Laboratories announced the introduction of Praluent, a Repatha biosimilar, in Canada. Such launches are ...